Researchers identify genetic mutations for rare disorder causing cognitive decline
More information: Jaroslaw Dulski et al, Global Presence and Penetrance of CSF1R -Related Disorder, Neurology Genetics (2024) ...
Nature22d
FDA approves CSF1R inhibitor for rare, non-cancerous joint tumours
The FDA has approved Ono’s CSF1R inhibitor vimseltinib (Romvimza) for adults with symptomatic tenosynovial giant cell tumours (TGCT) that are not suitable for surgical resection. It will compete ...